Singapore markets close in 5 hours 54 minutes
Straits Times Index
3,342.58 -0.77 (-0.02%) Nikkei
39,727.91 +386.37 (+0.98%) Hang Seng
17,797.83 +81.36 (+0.46%) FTSE 100
8,179.68 -45.65 (-0.55%) Bitcoin USD
61,646.64 +674.11 (+1.11%) CMC Crypto 200
1,286.44 +20.30 (+1.60%)
PCVX Jul 2024 115.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 1.0000 |
| Open | 0.9500 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 115.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.9500 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 46 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.